Workshop on Clinical Trial Endpoints for Acute Graft-versus-Host Disease (Acute GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT), and the Identification of Future Scientific Directions Needed to the Prevention of Acute GVHD
Tuesday, May 19, 2009 -
Wednesday, May 20, 2009
The primary focus was on validated endpoints that are ready for incorporation into clinical trials now or in the near future and on methods to address confounding issues unique to studies of acute GVHD. These will be used by the NHLBI-sponsored Blood and Marrow Transplant Clinical Trials Network (BMT CTN), and the materials will be made available publicly so that the endpoints may also be used by the oncology cooperative groups and corporate sponsors.
Dr. Nancy L. DiFronzo, NHLBI 301-435-0065
National Heart, Lung, and Blood Institute
From the National Center for Advancing Translational Sciences
From the National Institutes of Health